Plus Therapeutics Highlights Updates On Lead Program In Brain Cancer Indications
Plus Therapeutics Inc (NASDAQ:PSTV) presented data from two ongoing trials evaluating its lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, in recurrent…